CN115006377A - 二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 - Google Patents
二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 Download PDFInfo
- Publication number
- CN115006377A CN115006377A CN202210723873.XA CN202210723873A CN115006377A CN 115006377 A CN115006377 A CN 115006377A CN 202210723873 A CN202210723873 A CN 202210723873A CN 115006377 A CN115006377 A CN 115006377A
- Authority
- CN
- China
- Prior art keywords
- oxygen
- metformin
- pulmonary
- partial pressure
- lung tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 92
- 239000001301 oxygen Substances 0.000 title claims abstract description 92
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 89
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003105 metformin Drugs 0.000 title claims abstract description 52
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 231100000419 toxicity Toxicity 0.000 title claims description 5
- 230000001988 toxicity Effects 0.000 title claims description 5
- 230000036961 partial effect Effects 0.000 claims abstract description 32
- 230000006378 damage Effects 0.000 claims abstract description 14
- 230000036542 oxidative stress Effects 0.000 claims abstract description 13
- 206010037423 Pulmonary oedema Diseases 0.000 claims abstract description 7
- 208000005333 pulmonary edema Diseases 0.000 claims abstract description 7
- 230000000740 bleeding effect Effects 0.000 claims abstract description 6
- 230000004528 endothelial cell apoptotic process Effects 0.000 claims abstract description 6
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 5
- 210000004072 lung Anatomy 0.000 claims description 43
- 230000000069 prophylactic effect Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 230000000451 tissue damage Effects 0.000 claims description 9
- 231100000827 tissue damage Toxicity 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 abstract description 20
- 230000000607 poisoning effect Effects 0.000 abstract description 20
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 102000003952 Caspase 3 Human genes 0.000 abstract description 6
- 108090000397 Caspase 3 Proteins 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000037361 pathway Effects 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 abstract description 5
- 101710135898 Myc proto-oncogene protein Proteins 0.000 abstract description 5
- 101710150448 Transcriptional regulator Myc Proteins 0.000 abstract description 5
- 230000001276 controlling effect Effects 0.000 abstract description 4
- 208000004852 Lung Injury Diseases 0.000 abstract description 3
- 206010069363 Traumatic lung injury Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 231100000515 lung injury Toxicity 0.000 abstract description 3
- 210000004879 pulmonary tissue Anatomy 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000010444 Acidosis Diseases 0.000 description 6
- 230000007950 acidosis Effects 0.000 description 6
- 208000026545 acidosis disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000009189 diving Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 101000596404 Homo sapiens Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 2
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013417 toxicology model Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- -1 C-MYC Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011951 Decompression Sickness Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Abstract
本发明属于医药制备领域,特别涉及二甲双胍在制备预防高分压氧导致的肺型氧中毒的药物中的应用,二甲双胍显著降低高分压氧导致的肺组织出血、肺泡结构破坏,降低肺水肿;通过调控P38/38MAPK、p‑JAK1,p‑STAT3等炎症相关反应通路;减轻肺脏炎症;通过减少氧化应激产物,降低高压氧导致的氧化应激损伤;通过调控c‑myc,caspase‑3及bcl‑2通路减少支气管内皮细胞凋亡的比例。从而减轻肺型氧中毒导致的肺损伤。
Description
技术领域
本发明属于医药制备领域,特别涉及二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用。
背景技术
氧气是维持人类生存的必须物质。但机体吸入过多氧气,可导致氧中毒的发生。特别是在潜水领域中,呼吸高分压氧气及使用高压氧治疗减压病时,由于长时间吸入高分压、高浓度的氧气,超过了机体的适应能力,会导致氧中毒的发生。呼吸系统接触的氧分压高于其它器官,肺泡上皮细胞及支气管内皮细胞对氧比较敏感,所以肺脏是氧中毒的主要靶器官。肺型氧中毒的主要临床表现有咳嗽、胸骨后疼痛,呼吸急促,严重者可出现肺水肿、出血、甚至呼吸衰竭。从而影响了潜水作业的进行和临床高分压氧气的应用。
目前对于肺型氧中毒的发病机理,至今尚未完全明确。氧气进入体内代谢过程中,会产生大量的中间产物-氧自由基。在正常情况下,产生的氧自由基会被体内的抗氧化酶系统代谢掉,维持体内平衡。但若在短时间内吸入大量的高浓度、高分压氧气,产生的氧自由基超过体内的代谢水平,会导致体内氧自由基的富集。富集的氧自由基可损伤DNA、蛋白质、线粒体。虽然国内外进行了大量的研究,但目前对于肺型氧中毒的防治仍十分有限:氧自由基损伤机制研究尚未完全明确,临床上也缺乏特效的防治肺型氧中毒的药物。
二甲双胍是双胍类口服降糖类药物,其不仅可通过降低血浆胰岛素水平,减轻对胰岛素的抵抗作用、降低低密度脂蛋白胆固醇含量与总胆固醇含量,并可通过激活磷酸腺苷蛋白激酶信号的转导通路、促进肿瘤细胞凋亡、抗炎等对多种疾病起到预防及治疗作用。但目前未有研究证实可应用于预防肺型氧中毒。
发明内容
为了实现本发明的发明目的,采用了以下技术方案:
二甲双胍在制备预防和/或治疗高分压氧导致肺型氧中毒的药物中的应用;
进一步的,所述预防和/或治疗肺型氧中毒作用为降低肺组织损伤作用;
更进一步的,所述降低肺组织损伤作用包括显著降低高分压氧导致的肺组织出血、肺泡结构破坏以及降低肺水肿;减轻肺脏炎症;通过减少氧化应激产物,降低高压氧导致的氧化应激损伤;减少支气管内皮细胞凋亡的比例;
进一步的,所述药物为注射剂;
更进一步的,所述注射剂中二甲双胍的浓度为5~20mg/mL;进一步优选的,所述注射剂中二甲双胍的浓度为10mg/mL;
进一步的,所述二甲双胍腹腔注射的剂量为100~600mg/kg/d;进一步优选的,所述二甲双胍的腹腔注射的剂量是400mg/kg/d;
有益效果
本发明模型采用100%氧气暴露6h的肺型氧中毒模型,其主要是模拟潜水作业、潜水疾病治疗时需在高压环境下呼吸氧气,肺组织以出血、肺泡结构破坏最为明显,但也有渗出,炎症反应。本发明通过体内实验证明:二甲双胍具有预防和/或治疗高分压氧导致的肺型氧中毒作用,二甲双胍可显著降低高分压氧导致的肺组织出血、肺泡结构破坏,降低肺水肿;通过调控P38/38MAPK、p-JAK1,p-STAT3等炎症相关反应通路;减轻肺脏炎症;通过减少氧化应激产物,降低高压氧导致的氧化应激损伤;通过调控c-myc,caspase-3及bcl-2通路减少支气管内皮细胞凋亡的比例,从而减轻肺型氧中毒导致的肺损伤。
附图说明
图1是实施例1中不同剂量的二甲双胍预防性使用,对高分压氧导致的小鼠肺型氧中毒模型中肺湿干重比的影响对比图;
图2是实施例1中二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织损伤的影响对比图;
图3是实施例1中不同剂量二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织前致炎性因子及氧化代谢产物的改变对比图;
图4是实施例1中不同剂量二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织Tunel染色对比图;
图5是实施例1中不同剂量二甲双胍预防性保护作用对pERK、p38MAPK、cleaved-cas信号通路的调控;
图6是实施例1中不同剂量二甲双胍预防性使用通过调控JAK1磷酸化、STAT3磷酸化、调控BCL-2、c-Myc、P21磷酸化通路对肺型氧中毒起到预防性保护作用。
具体实施方式
下面结合实施例,对本发明作进一步说明:
本发明的实验所用的二甲双胍购自美国默沙东公司。
实施例1
1.1实验用注射药物:利用生理盐水,将二甲双胍配制成5-20mg/mL的溶液,制备成注射剂。
1.2实验动物和分组:40只雄性C57BL/6小鼠,体重30g左右,购买于上海毕凯实验动物公司。实验前1周饲养于海军医学研究所动物中心。将小鼠随机分为(1)空气暴露+生理盐水组、(2)高压氧暴露+生理盐水组、(3)高压氧暴露+二甲双胍100mg/Kg组、(4)高压氧暴露+二甲双胍200mg/Kg组、(5)高压氧暴露+二甲双胍400mg/Kg组,每组8只。
1.3实验方法:高分压氧暴露前3天,二甲双胍组((3)-(5)组)通过腹腔分别注射二甲双胍(100、200、400mg/kg),对照组通过腹腔注射等体积生理盐水((1)-(2)组)。第3天注射完后1h将实验动物置于动物氧舱内,加压至0.2MPa,100%v/v氧气暴露6h后,2分钟内减压出舱。取小鼠肺组织进行检测。
1.4实验结果:如图1所示,(1)空气暴露+生理盐水组小鼠肺组织的湿干重比为4.24±0.57(平均值±标准差),(2)高压氧暴露+生理盐水组小鼠肺组织的湿干重比为4.73±0.50,和(1)组相比较,明显增高,提示肺渗透性增加;(3)高分压氧暴露+二甲双胍100mg/Kg组的湿干重比为4.75±0.24,(4)高分压氧暴露+二甲双胍200mg/Kg组为4.59±0.22,(5)高分压氧暴露+二甲双胍400mg/Kg组为4.46±0.21。其中(5)组肺湿干重比和(2)组相比,显著下降,p值<0.05,说明二甲双胍400mg/Kg预处理可显著降低肺渗透性。图1是对高分压氧导致的小鼠肺型氧中毒模型中肺湿干重比的影响对比图。分别为(1)空气暴露+生理盐水组(Nomal),(2)高分压氧暴露+生理盐水组(HBO),(3)~(5)高分压氧暴露+二甲双胍不同剂量干预组((3)HBO+ML、(4)HBO+MM、(5)HBO+MH)。该研究结果说明二甲双胍400mg/Kg预防性使用可显著降低高压氧导致的肺水肿。
图2反映出实施例1中,二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织损伤的影响对比图。分别为(1)空气暴露+生理盐水组小鼠肺组织病理图(×20,即放大20倍),局部组织放大图(×63,即放大63倍);(2)高分压氧暴露+生理盐水组小鼠肺组织病理图(×20,即放大20倍),局部组织放大图(×63,即放大63倍);(3)二甲双胍400mg/Kg预防组小鼠肺组织病理图(×20),局部组织放大图(×63,即放大63倍)。对各组小鼠的肺组织病理检查发现,(2)高分压氧暴露+生理盐水组小鼠肺泡结构破坏,肺泡及支气管内见大量嗜伊红色液体和红细胞渗出。(3)二甲双胍400mg/Kg预防组小鼠肺泡结构破坏、肺泡壁水肿及肺泡腔内出血情况明显减轻。
图3反映出实施例1中,不同剂量二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织前致炎性因子及氧化代谢产物的改变对比图,其中图A为肺组织中前致炎性因子TNF-α及IL-6的含量;图B为肺组织中氧化代谢产物MDA及GPx的含量。和空气暴露组相比较,高分压氧暴露+生理盐水组小鼠肺组织中前致炎性因子,TNF-α及IL-6的含量及氧化代谢产物,MDA及GPx的含量明显增高,而二甲双胍预防性使用可显著降低小鼠肺组织中前致炎性因子及氧化代谢产物含量。这部分结果说明二甲双胍预防性使用可减轻高压氧导致的肺组织炎性反应,通过减少氧化应激产物,降低高压氧导致的氧化应激损伤。
图4反映出实施例1中,不同剂量二甲双胍预防性使用对高分压氧导致的小鼠肺型氧中毒模型中肺组织Tunel染色对比图。其中“Tunel”表示单染的探针(红色),“merge”表示和Dapi染色(蓝色)复染。分别为(1)空气暴露+生理盐水组(Nomal),(2)高分压氧暴露+生理盐水组(HBO),(3)~(5)高分压氧暴露+二甲双胍不同剂量干预组((3)HBO+ML、(4)HBO+MM、(5)HBO+MH),说明了Tunel荧光染色显示,和(1)空气暴露组相比较,(2)高压氧暴露+生理盐水组小鼠肺组织中凋亡细胞数明显增高,主要表现在支气管内皮细胞,而二甲双胍预防性使用可显著降低小鼠肺组织中凋亡细胞。该结果证实二甲双胍预防性使用可减少高压氧导致的支气管内皮细胞凋亡。
图5是实施例1中,不同剂量二甲双胍预防性保护作用对pERK、p38MAPK、cleaved-cas信号通路的调控。图5A表示ERK,磷酸化ERK、p38及磷酸化p38,caspase3及cleaved-caspase3的代表性免疫印迹图;图5B-5D分别表示各组磷酸化ERK/ERK、磷酸化p38/p38、cleaved-caspase3/caspase3的统计学分析图。Western检测发现,和(1)空气暴露组相比较,(2)高压氧暴露+生理盐水组小鼠肺组织中P38/38MAPK含量显著降低,而二甲双胍预防性使用可显著增加P38/38MAPK含量;cleaved-caspase-3/caspase-3的含量在二甲双胍中高剂量使用时反而明显增高。
图6是实施例1中,不同剂量二甲双胍预防性使用通过调控JAK1磷酸化、STAT3磷酸化、调控BCL-2、c-Myc、P21磷酸化通路对肺型氧中毒起到预防性保护作用。图6A表示磷酸化JAK1,磷酸化STAT3、磷酸化STAT1,Bcl-2、C-MYC及P21的代表性免疫印迹图;图6B-6F分别表示各组小鼠肺组织中蛋白表达的统计学分析图。Western检测发现,和(1)空气暴露组相比较,(2)高压氧暴露+生理盐水组小鼠肺组织中p-JAK1,p-STAT3,Bcl-2蛋白显著降低,二甲双胍预防性使用可显著改善这些降低的蛋白含量;p-STAT1的含量在二甲双胍低剂量组显著增高,而中高剂量组则明显降低。
1.5结论:二甲双胍预防性使用对高分压氧导致的肺型氧中毒具有明显的保护作用,显著降低高分压氧导致的肺组织出血、肺泡结构破坏,降低肺水肿;通过调控P38/38MAPK、p-JAK1,p-STAT3等炎症相关反应通路;减轻肺脏炎症;通过减少氧化应激产物,降低高压氧导致的氧化应激损伤;通过调控c-myc,caspase-3及bcl-2通路减少支气管内皮细胞凋亡的比例。从而减轻肺型氧中毒导致的肺损伤。
综上所述,通过上述实验可证实,二甲双胍可通过下调p-JAK1,p-STAT3,Bcl-2通路,降低肺脏渗透性,减轻肺脏炎症,降低肺组织细胞的凋亡率,减少氧化应激产物,从而对肺型氧中毒起到保护作用。
以上所述为本发明的较佳实施例而已,但本发明不应该局限于该实施例所公开的内容。所以凡是不脱离本发明所公开的精神下完成的等效或修改,都落入本发明保护的范围。
Claims (9)
1.二甲双胍在制备预防和/或治疗高分压氧导致肺型氧中毒的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述预防和/或治疗肺型氧中毒作用为降低肺组织损伤作用。
3.根据权利要求2所述的应用,其特征在于,所述降低肺组织损伤作用为显著降低高分压氧导致的肺组织出血、肺泡结构破坏以及降低肺水肿。
4.根据权利要求2所述的应用,其特征在于,所述降低肺组织损伤作用为减轻肺脏炎症。
5.根据权利要求2所述的应用,其特征在于,所述降低肺组织损伤作用为通过减少氧化应激产物,降低高压氧导致的氧化应激损伤。
6.根据权利要求2所述的应用,其特征在于,所述降低肺组织损伤作用为减少支气管内皮细胞凋亡的比例。
7.根据权利要求1~6任一项所述的应用,其特征在于,所述所述药物为注射剂。
8.根据权利要求7所述的应用,其特征在于,所述注射剂中二甲双胍的浓度为5~20mg/mL。
9.根据权利要求8所述的应用,其特征在于,所述注射剂中二甲双胍的浓度为10mg/mL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210723873.XA CN115006377A (zh) | 2022-06-24 | 2022-06-24 | 二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210723873.XA CN115006377A (zh) | 2022-06-24 | 2022-06-24 | 二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115006377A true CN115006377A (zh) | 2022-09-06 |
Family
ID=83076365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210723873.XA Pending CN115006377A (zh) | 2022-06-24 | 2022-06-24 | 二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115006377A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727504A (zh) * | 2016-11-24 | 2017-05-31 | 中国人民解放军海军医学研究所 | 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用 |
WO2021248688A1 (zh) * | 2020-06-08 | 2021-12-16 | 广州新民培林医药科技有限公司 | Itpp在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用 |
-
2022
- 2022-06-24 CN CN202210723873.XA patent/CN115006377A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106727504A (zh) * | 2016-11-24 | 2017-05-31 | 中国人民解放军海军医学研究所 | 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用 |
WO2021248688A1 (zh) * | 2020-06-08 | 2021-12-16 | 广州新民培林医药科技有限公司 | Itpp在制备预防和/或治疗缺血缺氧损伤及肺损伤的药物中的应用 |
Non-Patent Citations (3)
Title |
---|
XUEYU CHEN ET AL.: "Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 309, 5 June 2015 (2015-06-05), pages 262 * |
屠伟峰: "麻醉相关并发症处理学", 30 September 2005, 中国医药科技出版社, pages: 696 * |
李宁 黄怀: "高压氧临床治疗学", 30 September 2007, 中国协和医科大学出版社, pages: 264 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Geng et al. | The effects of hyperbaric oxygen on macrophage polarization after rat spinal cord injury | |
US20210000883A1 (en) | Method and System for Reducing the Likelihood of Osteoporosis | |
Zhang et al. | Shen-Fu injection attenuates postresuscitation lung injury in a porcine model of cardiac arrest | |
WO2019089165A1 (en) | Orally administered composition for treating cystic fibrosis, copd, asthma and other inflammatory conditions | |
Cui et al. | Methane-rich saline alleviates CA/CPR brain injury by inhibiting oxidative stress, microglial activation-induced inflammatory responses, and ER stress-mediated apoptosis | |
US9901602B2 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
KR100696417B1 (ko) | 진세노사이드 Rb₁을 함유하는 뇌혈관 재생ㆍ재구축 촉진제 및 신경조직 이차변성 억제제 | |
Sun et al. | Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine | |
Feng et al. | Acute diquat poisoning causes rhabdomyolysis | |
Li-Li et al. | 5, 7, 2’, 4’, 5’-Pentamethoxyflavanone regulates M1/M2 macrophage phenotype and protects the septic mice | |
Shoaib et al. | Metformin-mediated mitochondrial protection post-cardiac arrest improves EEG activity and confers neuroprotection and survival benefit | |
US11951139B2 (en) | Method and system for reducing the likelihood of osteoporosis | |
CN115006377A (zh) | 二甲双胍在制备预防和/或治疗肺型氧中毒药物中的应用 | |
US8927601B2 (en) | Uses of N-butylidenephthalide in treating a liver injury and improving liver function | |
CN112741826A (zh) | 氯硝柳胺的新应用 | |
CN106727504B (zh) | 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用 | |
RU2541831C2 (ru) | Способ моделирования и фармакологической коррекции острого повреждения легких в эксперименте | |
Kilic et al. | The effects of fusidic acid on the inflammatory response in rats | |
CN101897719B (zh) | 一种用于治疗烟雾吸入性肺损伤的药物组合物 | |
CN115708823B (zh) | 熊竹素在制备预防和/或治疗脓毒症肺损伤的药物中的应用 | |
CN109589409A (zh) | 药物联合制剂及厚朴酚在制备化疗药物增效减毒剂中的应用 | |
Hosseini Nezhad Motlagh et al. | The protective effects of Olive leaf extract on Type 2 diabetes, the expression of liver superoxide dismutase and total antioxidant capacity of plasma in rats | |
CN114306350B (zh) | 胆固醇硫酸盐在制备预防脓毒症的药物中的用途 | |
CN114306355B (zh) | 二苯乙烯苷在制备预防或治疗失血性休克药物中的应用 | |
CN113908169B (zh) | 一种药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |